Announcement:
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma
Contact
Curious about our work? Get in touch.
InvestorsJason Silversinvestors@generatebiomedicines.com
Media InquiriesMegan McLaughlinpr@generatebiomedicines.com
Collaboration& PartnershipsSahm Nasseripartner@generatebiomedicines.com
Clinical Trialssolairiastudy@generatebiomedicines.com